NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Forecast & News

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

Dova Pharmaceuticals Inc (NASDAQ:DOVA) posted its earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.03. The business earned $3.52 million during the quarter, compared to analysts' expectations of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' Earnings History.

6 brokers have issued 1-year price objectives for Dova Pharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they anticipate Dova Pharmaceuticals' stock price to reach $26.42 in the next year. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

News stories about DOVA stock have trended extremely negative on Sunday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Dova Pharmaceuticals.

Some companies that are related to Dova Pharmaceuticals include Blueprint Medicines (BPMC), Zai Lab (ZLAB), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Axsome Therapeutics (AXSM), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Alkermes (ALKS), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Epizyme (EPZM), ArQule (ARQL), Zogenix (ZGNX) and ChemoCentryx (CCXI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), TESARO (TSRO), TherapeuticsMD (TXMD), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Heron Therapeutics (HRTX) and Immunomedics (IMMU).

(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DOVA stock can currently be purchased for approximately $28.04.

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

The official website for Dova Pharmaceuticals is http://www.dova.com/.

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]